Home › Biotech Mailbag: Duchenne Drama, CAR-T Trouble, ASCO
 

Keywords :   


Biotech Mailbag: Duchenne Drama, CAR-T Trouble, ASCO

2015-06-05 15:01:16| Biotech - Topix.net

It's weird, somewhat inappropriate and definitely risky for Biomarin given its DMD drug drisapersen is currently under FDA review. Sarepta Therapeutics If you're unsure what Steven is referring to, Biomarin and PTC Therapeutics are co-sponsoring an investor "symposium" on June 22 in New York City titled, Advances in Duchenne Muscular Dystrophy Natural History and Biomarkers .

Tags: cart trouble drama biotech

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.10Tropical Storm Milton Public Advisory Number 2
05.10Hurricane Kirk Graphics
05.10Hurricane Kirk Forecast Discussion Number 26
05.10Tropical Storm Milton Graphics
05.10Hurricane Kirk Wind Speed Probabilities Number 26
05.10Hurricane Leslie Graphics
05.10Hurricane Kirk Public Advisory Number 26
05.10Summary for Hurricane Kirk (AT2/AL122024)
More »